ACOR
$0.41
Acorda Therapeutics
$.00
.98%
ACOR
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Wednesday
Aug 10
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ACOR reports earnings?
Beat
Meet
Miss

Where is ACOR's stock price going from here?
Up
Flat
Down
Stock chart of ACOR
Analysts
Summary of analysts' recommendations for ACOR
Score
Grade
Pivots
Resistance
$0.49
$0.47
$0.44

$0.42

Support
$0.39
$0.37
$0.34
Tweet
Growth
Description
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Peers
BiogenNeurocrine BiosciencesAmgenGilead SciencesBluebird BioBioCryst PharmaceuticalsSeagen Inc.RepligenNovavaxQiagen N.V.